Ayala Pharmaceuticals
Dana Gelbaum is a biopharmaceutical executive with 20 years of experience in pre-commercial and business development. Previously Dana was Vice President, Global Marketing and Corporate Development at Chiasma (NASDAQ:CHMA), a biopharmaceutical company focused on orphan diseases. Dana led pre-commercial planning of octreotide capsules and select business development activities. Prior to Chiasma, Dana was Director of Business Development at Recoly N.V., a biopharmaceutical company focused on hemophilia. Previously, Dana was an Associate at Johnson & Johnson Development Corporation (JJDC), J&J’s investment arm, focusing on investments in biopharmaceutical and medical devices in Europe and Israel. Prior to JJDC, she was an Associate in Ernst & Young Corporate Finance Life Science Department. Dana received her MSc, cum laude, and MBA from Tel Aviv University.
This person is not in any offices
Ayala Pharmaceuticals
Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations.